15,056 Shares in Phreesia, Inc. (NYSE:PHR) Bought by Raymond James Financial Inc.

Raymond James Financial Inc. bought a new position in shares of Phreesia, Inc. (NYSE:PHR) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 15,056 shares of the company’s stock, valued at approximately $379,000.

A number of other institutional investors have also added to or reduced their stakes in the business. ExodusPoint Capital Management LP grew its holdings in shares of Phreesia by 448.6% during the fourth quarter. ExodusPoint Capital Management LP now owns 174,971 shares of the company’s stock worth $4,402,000 after purchasing an additional 143,077 shares in the last quarter. Norges Bank bought a new stake in Phreesia during the fourth quarter valued at approximately $2,804,000. Nicholas Company Inc. purchased a new position in Phreesia in the 4th quarter worth approximately $2,452,000. JPMorgan Chase & Co. increased its holdings in shares of Phreesia by 144.2% in the 4th quarter. JPMorgan Chase & Co. now owns 145,716 shares of the company’s stock worth $3,666,000 after buying an additional 86,040 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Phreesia by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 4,823,110 shares of the company’s stock valued at $121,349,000 after buying an additional 61,048 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CFO Balaji Gandhi sold 28,759 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $30.00, for a total value of $862,770.00. Following the completion of the sale, the chief financial officer now owns 116,174 shares of the company’s stock, valued at $3,485,220. This trade represents a 19.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Evan Roberts sold 16,005 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $30.00, for a total transaction of $480,150.00. Following the transaction, the chief operating officer now directly owns 748,302 shares in the company, valued at approximately $22,449,060. The trade was a 2.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 111,640 shares of company stock valued at $3,094,167. Insiders own 5.80% of the company’s stock.

Phreesia Trading Up 0.7 %

NYSE:PHR opened at $25.57 on Friday. The firm has a market capitalization of $1.50 billion, a P/E ratio of -17.39 and a beta of 0.74. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The company has a fifty day moving average of $25.08 and a 200 day moving average of $24.68.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on PHR shares. DA Davidson reduced their target price on Phreesia from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Monday, April 14th. Needham & Company LLC reiterated a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research report on Thursday, March 13th. Citigroup raised their price objective on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $33.00 target price (up previously from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Finally, KeyCorp decreased their price target on shares of Phreesia from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 16th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.